These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 16599048)

  • 1. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G; Greenbaum E; Zakay-Rones Z
    Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
    Gorse GJ; O'Connor TZ; Newman FK; Mandava MD; Mendelman PM; Wittes J; Peduzzi PN
    J Infect Dis; 2004 Jul; 190(1):11-9. PubMed ID: 15195238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M; Yehuda AB; Schein MH; Friedlander Y; Naveh P; Greenbaum E; Schlesinger M; Levy R; Zakay-Rones Z; Friedman G
    J Med Virol; 2000 May; 61(1):100-6. PubMed ID: 10745240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative studies on the vaccination of mice with inactivated influenza virus administered by the aerosol technique, by the intranasal or intramuscular route (author's transl)].
    Neukirch M; Bauer K; Barth S
    Zentralbl Bakteriol Orig A; 1979 Dec; 245(4):409-20. PubMed ID: 44935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of antineuraminidase antibodies in protection against influenza].
    Aymard M; Gerentes L; Kessler N
    Bull Acad Natl Med; 1998; 182(8):1723-36; discussion 1736-7. PubMed ID: 10188318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity.
    Bakke H; Samdal HH; Holst J; Oftung F; Haugen IL; Kristoffersen AC; Haugan A; Janakova L; Korsvold GE; Krogh G; Andersen EA; Djupesland P; Holand T; Rappuoli R; Haneberg B
    Scand J Immunol; 2006 Mar; 63(3):223-31. PubMed ID: 16499576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA; Cate TR; Nino D; Huggins LL; Six HR; Quarles JM; Couch RB
    J Infect Dis; 2001 Jan; 183(2):329-332. PubMed ID: 11110645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-neuraminidase antibody response in serum and nasal secretions following intranasal or subcutaneous inactivated A2-Hong Kong-68 influenza virus vaccine.
    Fedson DS; Fulk RV; Huber MA; Reisberg MA; Kasel JA
    J Immunol; 1971 Sep; 107(3):730-7. PubMed ID: 4999093
    [No Abstract]   [Full Text] [Related]  

  • 17. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antibody response to mucosal (NASAL) and subcutaneous stimulation of influenza virus in patients with IgA nephropathy.
    Kashem A; Endoh M; Yano N; Yamauchi F; Nomoto Y; Sakai H
    Tokai J Exp Clin Med; 1992 May; 17(1):23-8. PubMed ID: 1523689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase antibodies in serum and nasal washings after immunization by means of live and killed whole virion, split virion and subunit (HA and N) influenza vaccines.
    Kuwert EK; Höher PG; Werner J; Scheiermann N; Thraenhart O; Müller B; Kleber G
    Dev Biol Stand; 1977 Jun 1-3; 39():77-83. PubMed ID: 604137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M; Greenbaum E; Ben-Yehuda A; Oster M; Yeu'l E; Heimann S; Levy R; Friedman G; Zakay-Rones Z
    Vaccine; 2003 Mar; 21(11-12):1180-6. PubMed ID: 12559796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.